Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LAP3 | P28838 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | PGK1 | P00558 | 3/20 | 0.37 |
| ▸ | PGK2 | P07205 | 3/20 | 0.37 |
| ▸ | ANPEP | P15144 | 1/20 | 0.33 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.33 |
| ▸ | TYMS | P04818 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | FDPS | P14324 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | SLC34A1 | Q06495 | 1/20 | 0.31 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.30 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5372176 | 0.75 | — | — | |
| SCHEMBL27313311 | 0.72 | — | — | |
| SCHEMBL27495089 | 0.72 | — | — | |
| SCHEMBL94341 | 0.72 | — | — | |
| SCHEMBL919194 | 0.64 | — | — | |
| SCHEMBL4105786 | 0.64 | KDM4E (0.43) | LAP3KDM4EMMP2THRBMAPK1 | |
| SCHEMBL1409859 | 0.64 | KDM4E (0.43) | LAP3KDM4EMMP2THRBMAPK1 | |
| Phosphoric Acid SCHEMBL7941251 | 0.61 | CA2 (0.46) | LAP3KDM4EMMP2THRBMAPK1 | |
| Phosphoric Acid SCHEMBL873751 | 0.61 | CA2 (0.46) | LAP3KDM4EMMP2THRBMAPK1 | |
| Phosphoric Acid SCHEMBL237016 | 0.61 | CA2 (0.46) | LAP3KDM4EMMP2THRBMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6071434-A | Phosphino derivatives | ALBRIGHT & WILSON UK LIMITED (GB) | 2000-06-06 | — | — | US | claimed |
| US-20240182504-A1 | BISPHOSPHONATE QUINOLONE CONJUGATES AND USES THEREOF | BIOVINC LLC (US) | 2024-06-06 | — | — | US | disclosed |
| US-11840549-B2 | Bisphosphonate quinolone conjugates and uses thereof | BIOVINC, LLC (US) | 2023-12-12 | — | — | US | disclosed |
| US-20230109597-A1 | CLEANING COMPOSITION | FUJIMI INCORPORATED (JP) | 2023-04-06 | — | — | US | disclosed |
| US-20210395645-A1 | CLEANING LIQUID | FUJIFILM ELECTRONIC MATERIALS CO., LTD. (JP) | 2021-12-23 | — | — | US | disclosed |
| US-11203731-B2 | Composition for surface treatment and method of producing the same, surface treatment method, and method of producing semiconductor substrate | FUJIMI INCORPORATED (JP) | 2021-12-21 | — | — | US | disclosed |
| US-20210130735-A1 | COMPOSITION FOR SURFACE TREATMENT AND METHOD OF PRODUCING THE SAME, SURFACE TREATMENT METHOD, AND METHOD OF PRODUCING SEMICONDUCTOR SUBSTRATE | FUJIMI INCORPORATED (JP) | 2021-05-06 | — | — | US | disclosed |
| US-20210101920-A1 | BISPHOSPHONATE QUINOLONE CONJUGATES AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-04-08 | — | — | US | disclosed |
| US-10954479-B2 | Composition for surface treatment and surface treatment method using the same | FUJIMI INCORPORATED | 2021-03-23 | — | — | US | disclosed |
| US-10865220-B2 | Bisphosphonate quinolone conjugates and uses thereof | BIOVINC, LLC (US) | 2020-12-15 | — | — | US | disclosed |
| US-20070298066-A1 | Biodegradable linkers for molecular therapies | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2007-12-27 | — | — | US | disclosed |
| EP-1807092-A2 | BIODEGRADABLE LINKERS FOR MOLECULAR THERAPIES | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2007-07-18 | — | — | EP | disclosed |
| EP-1471921-A4 | COUNTERACTING BIOPROSTHETIC CALCIFICATION | PHILADELPHIA CHILDREN HOSPITAL (US) | 2007-06-20 | — | — | EP | disclosed |
| US-7156881-B2 | Counteracting bioprosthetic calcification | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2007-01-02 | — | — | US | disclosed |
| WO-2006052790-A2 | BIODEGRADABLE LINKERS FOR MOLECULAR THERAPIES | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2006-05-18 | — | — | WO | disclosed |
| EP-1471921-A2 | COUNTERACTING BIOPROSTHETIC CALCIFICATION | The Children's Hospital of Philadelphia (US) | 2004-11-03 | — | — | EP | disclosed |
| US-20030196274-A1 | Counteracting bioprosthetic calcification | CHILDREN'S HOSPITAL OF PHILADELPHIA | 2003-10-23 | — | — | US | disclosed |
| WO-2003057177-A2 | COUNTERACTING BIOPROSTHETIC CALCIFICATION | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2003-07-17 | — | — | WO | disclosed |
| US-20030044408-A1 | Surface modification for improving biocompatibility | THE CHILDREN'S HOSPITAL OF PHILADELPHIA | 2003-03-06 | — | — | US | disclosed |
| WO-2002103004-A1 | SURFACE MODIFICATION FOR IMPROVING BIOCOMPATIBILITY | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2002-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10865220-B2 | Bisphosphonate quinolone conjugates and uses thereof | BPGM, PHPT1, NQO2 | LAP3 2804/4885KDM4E 3437/4885MMP2 4455/4885 |
| US-20240182504-A1 | BISPHOSPHONATE QUINOLONE CONJUGATES AND USES THEREOF | BPGM, PHPT1, NQO2 | LAP3 2804/4885KDM4E 3437/4885MMP2 4455/4885 |
| US-11840549-B2 | Bisphosphonate quinolone conjugates and uses thereof | BPGM, PHPT1, NQO2 | LAP3 2804/4885KDM4E 3437/4885MMP2 4455/4885 |
| US-20070298066-A1 | Biodegradable linkers for molecular therapies | BMP2, ECPAS, CD44 | LAP3 486/4885KDM4E 1958/4885MMP2 13/4885 |
| US-20210101920-A1 | BISPHOSPHONATE QUINOLONE CONJUGATES AND USES THEREOF | BPGM, PHPT1, NQO2 | LAP3 2804/4885KDM4E 3437/4885MMP2 4455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.